Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp.

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 1, 2012, Pages 53-56

  Martos, Antonia Isabel ^a   Martín Mazuelos, Estrella ^a   Romero, Ana ^a   Serrano, Carmen ^a   González, Trinidad ^a   Almeida, Carmen ^a   Puche, Beatriz ^a   Cantón, Emilia ^b   Pemán, Javier ^b   Espinel Ingroff, Ana ^c  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aspergillus; Disk diffusion; Echinocandin; Susceptibility testing

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN;

AGAR MEDIUM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS GLAUCUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BROTH DILUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISK DIFFUSION; FUNGUS ISOLATION; FUSARIUM; INTERMETHOD COMPARISON; MINIMAL EFFECTIVE CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUELLER HINTON AGAR; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CULTURE MEDIA; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84860712938     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.01.006     Document Type: Article

References (26)

1. Arikan S., Paetznick V., Rex J.H. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 2002, 46:3084-3087.
2. Arikan S., Yurdakul P., Hascelik G. Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob. Agents Chemother. 2003, 47:2640-2643.
3. Cappelletty D., Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007, 27:369-388.
4. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard - second edition, M38-A2 2008, CLSI, Wayne, PA.
5. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard - third edition, M27-A3 2008, CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute (CLSI) Method for antifungal disk diffusion susceptibility testing of non-dermatophyte filamentous fungi (M51-A) 2010, CLSI, Wayne, PA.
7. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008, 46:1813-1821.
8. Diekema D.J., Messer S.A., Hollis R.J., Jones R.N., Pfaller M.A. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 2003, 41:3623-3626.
9. Espinel-Ingroff A., Arthington-Skaggs B., Iqbal N., Ellis D., Pfaller M.A., Messer S., et al. A multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J. Clin. Microbiol. 2007, 45:1811-1820.
10. Espinel-Ingroff A., Fothergill A., Fuller J., Johnson E., Pelaez T., Turnidge J. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol 2011, 55:2855-2859.
11. Jones R.N., Kirby J.T., Messer S.A., Sheehan D.J. Development of anidulafungin for disk diffusion susceptibility testing against Candida spp. Diagn. Microbiol. Infect. Dis. 2007, 58:371-374.
12. Lin S., Schranz J., Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 2001, 32:358-366.
13. López-Oviedo E., Aller A.I., Martín C., Castro C., Ramírez M., Pemán J.M., et al. Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method. Antimicrob. Agents Chemother. 2006, 50:1108-1111.
14. Maida C.M., Milici M.E., Trovato L., Oliveri S., Amodio E., Spreghini E., et al. Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. J. Clin. Microbiol. 2008, 46:4071-4074.
15. Marr K.A., Carter R.A., Crippa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2002, 34:909-917.
16. Martín-Mazuelos E. Anidulafungin vicuron. IDrugs 2003, 6:980-986.
17. Metcalf S.C., Dockrell D.H. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007, 55:287-299.
18. Morris M.I., Vilmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006, 63:1693-1703.
19. Morrison V.A. Echinocandin antifungals: review and update. Expert Rev Anti Infect Ther 2006, 4:325-342.
20. Manual of Clinical Microbiology 2007, ASM Press, Washington. 9th Ed. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, M.A. Pfaller (Eds.).
21. Oakley K.L., Moore C.B., Denning W. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. 1998, 42:2726-2730.
22. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 2008, 46:150-156.
23. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Diagn. Microbiol. Infect. Dis. 2010, 67:56-60.
24. Serrano M.C., Ramírez M., Morilla D., Valverde A., Chávez M., Espinel-Ingroff A., et al. A comparative study of the disk diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp. J Antimicrob Chemother 2004, 53:739-742.
25. Tawara S., Ikeda F., Maki K., Morishita Y., Otomo K., Teratani N., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 2000, 44:57-62.
26. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disease Society of America. Clin. Infect. Dis. 2008, 46:327-360.